<DOC>
	<DOCNO>NCT01034878</DOCNO>
	<brief_summary>Sunitinib register treatment first-line therapy metastatic clear-cell carcinoma kidney.Data Expanded Access Study show activity also non-clear cell renal cancer ( NCCRC ) . The aim study prospectively evaluate anti-tumor activity safety sunitinib first-line therapy metastatic NCCRC patient .</brief_summary>
	<brief_title>Sunitinib Metastatic Renal Cancer</brief_title>
	<detailed_description>This prospective , open label , multicenter phase II study evaluate efficacy Sunitinib ( advanced/metastatic renal cancer non-clear cell histology ( papillary chromophobe ) . Sunitinib administer orally dose 50 mg daily , six week cycle consist 4 week treatment follow 2 week . Treatment study drug continue tumor progression unacceptable toxicity . The planned total sample size study 55 patient . Approximately 10 study site involve .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically proven diagnosis metastatic renal cancer nonclear cell No previous treatment Prior treatment antiangiogenetic compound Symptomatic and/or unstable preexist brain metastasis Severe uncontrolled cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>